Zealand Pharma A/S ZEAL
Set alert
17.59 +17.59 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -6.49
- Beta
- 1.34
- Short ratio
- 37.96
- Inst. own
- 1.75%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 10, 2022
- 50-d avg
- 17.73
- 200-d avg
- 15.57
- 1y target
- 32.30
Analyst view
Consensus: buy
Buy
Price target (mean) 32.30
Ratings (0m) 2 2 buy · 0 hold · 0 sell
- Strong buy0
- Buy2
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 2
- 1 month ago 2
- 2 months ago 3
- 3 months ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.71 | -0.71 – -0.71 | -0.70 | -1.4% | 2.64M | -82.2% | 1 |
| Next quarter | -0.67 | -0.67 – -0.67 | -0.91 | +26.4% | 2.64M | -65.0% | 1 |
| Current year | -3.24 | -3.46 – -3.02 | -3.31 | +2.1% | 37.11M | -9.1% | 2 |
| Next year | -2.71 | -2.84 – -2.57 | -3.24 | +16.4% | 53.76M | +44.9% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| May 13, 2022 | Needham | Maintained | — | Buy |
| Nov 13, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Oct 13, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Aug 14, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Apr 15, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Mar 31, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Jan 17, 2020 | Morgan Stanley | Maintained | — | Overweight |
| Nov 19, 2019 | Jefferies | Downgrade | Buy | Hold |
| Nov 15, 2019 | Morgan Stanley | Maintained | — | Overweight |
| Oct 15, 2019 | Goldman Sachs | Upgrade | Neutral | Buy |
| Sep 20, 2019 | Guggenheim | Initiated | — | Buy |
| Aug 19, 2019 | Morgan Stanley | Maintained | — | Overweight |
| Sep 27, 2017 | Goldman Sachs | Initiated | — | Buy |
| Sep 5, 2017 | Guggenheim | Initiated | — | Buy |